Onset is a PK/PD construct describing the modeled point at which the rising concentration trajectory enters the region of a concentration–effect relationship associated with the beginning of a defined modeled response. It is therefore not a single PK parameter and is distinct from peak concentration, maximal modeled effect, or the later decline associated with duration. The early trajectory is shaped first by absorption processes, including dissolution, gastric emptying, intestinal availability, absorption rate, and the timing of systemic input. As drug enters the central compartment, distribution begins to interact with absorption, creating a transition in which systemic concentration reflects both continuing input and movement into other compartments. Early concentration geometry is consequently determined by the rate and extent of systemic input together with distribution and early elimination processes. The PD layer then determines how this concentration trajectory maps onto the concentration–effect curve. Potency determines the concentration scale of the modeled response, while slope determines how sharply response changes as concentration rises. Pathway sensitivity can further influence the concentration region associated with a defined modeled response. Onset is therefore a combined PK/PD timing descriptor rather than a clinical outcome. The broader mechanistic framework is presented in the overview.
Sildenafil and avanafil can produce different modeled onset geometries when their absorption, distribution, metabolic, and concentration–effect parameters differ. Absorption rate determines the steepness of early systemic input, while gastric emptying and intestinal availability can influence when that input begins and how it is distributed over time. Distribution can simultaneously remove drug from the central compartment into peripheral compartments, modifying the relationship between continuing absorption and observed plasma concentration. Early metabolic turnover can additionally influence the emerging concentration trajectory, particularly as systemic input and elimination begin to overlap. These processes can shift the location and shape of the early ascending profile without making onset identical to peak formation. The same early concentration geometry can also map differently onto a PD curve if potency, slope, or pathway sensitivity differs. Thus, onset is connected to both PK input and PD coupling but remains distinct from the later peak and decline regions of the trajectory. Peak formation and subsequent persistence can be examined through peak effect comparison and duration comparison. The relevant upstream determinants are described through absorption differences and distribution differences.
Onset variability can originate in either the PK or PD layer of the modeled system. PK variability can alter the timing and shape of the concentration rise through differences in absorption rate, gastric emptying, systemic input, distribution, metabolic turnover, and clearance. A shift in any of these parameters can move the concentration trajectory relative to a fixed concentration–effect curve. PD variability operates differently: changes in potency, concentration–effect slope, maximal modeled effect, or pathway sensitivity can alter where a defined response begins even when the underlying concentration-time profile is unchanged. Consequently, two modeled onset differences can have different mechanistic origins. One may result from a shift in early exposure geometry, while another may result from a change in concentration–effect coupling. The distinction is particularly important when comparing sildenafil and avanafil because PK processes determine the concentration delivered to the PD system, whereas PD parameters determine how that concentration is translated into modeled response. The separation between these layers is developed in pk variability and pd variability.
Absorption rate is a primary determinant of early concentration formation because it controls how quickly drug enters the systemic compartment. Dissolution determines the availability of drug for subsequent absorption, while gastric emptying influences the timing of intestinal entry. Intestinal availability and absorption extent determine how much drug ultimately contributes to systemic input, whereas absorption rate determines how that input is distributed over time. As systemic entry begins, distribution occurs simultaneously, so the observed central concentration reflects the balance between continuing absorption and movement into peripheral compartments. This distribution–absorption transition can change the slope and curvature of the early concentration-time profile. Systemic input timing therefore cannot be reduced to a single moment: it is a temporal process involving the initiation, rate, and extent of drug entry. Early concentration geometry emerges from the combined effects of these input parameters, distribution, and early elimination. A defined onset point is then obtained only after this PK trajectory is considered together with the PD concentration–effect relationship. The underlying absorption determinants are described through absorption differences.
Sildenafil and avanafil can exhibit distinct modeled onset geometry when their absorption-rate parameters and distribution characteristics interact differently with systemic input. A faster modeled input rate produces a steeper early concentration rise, whereas a slower input distributes systemic entry over a broader interval. Differences in gastric emptying sensitivity can alter the timing of intestinal entry, while differences in absorption extent can modify the magnitude of the emerging exposure profile. At the same time, distribution removes drug from the central compartment and establishes concentration gradients between plasma and peripheral compartments. The observed early profile is therefore the result of concurrent absorption and distribution rather than either process in isolation. Early metabolic turnover can further modify the concentration trajectory as systemic input continues. These mechanisms can shift the modeled location of onset and also influence the concentration profile leading toward the peak. The structural relationships among compartmental movement and exposure are described through distribution differences and metabolism differences.
| Onset Domain | Sildenafil | Avanafil | Link |
|---|---|---|---|
| Absorption Rate | Shapes early concentration rise. | Shapes early concentration rise. | absorption differences |
| Systemic Input Timing | Determines timing of initial systemic concentration formation. | Determines timing of initial systemic concentration formation. | overview |
| Distribution–Absorption Transition | Influences early concentration geometry. | Influences early concentration geometry. | distribution differences |
| Early Metabolic Turnover | Shapes concentration decline as early input continues. | Shapes concentration decline as early input continues. | metabolism differences |
| Early PK Geometry | Defines the concentration trajectory entering the PD response region. | Defines the concentration trajectory entering the PD response region. | peak effect comparison |
The PD component of onset begins when the early concentration trajectory enters a defined region of the concentration–effect relationship. Potency determines the concentration scale at which a specified modeled response becomes apparent, while slope determines how rapidly the modeled response changes as concentration increases through that region. Maximal modeled effect establishes the upper response boundary but does not itself determine the initial point of the response curve. Pathway sensitivity can further influence how changes in concentration or PDE5 interaction propagate through the downstream signaling model. In an NO–sGC–cGMP framework, upstream NO activates soluble guanylate cyclase and promotes cGMP formation, while PDE5 regulates cGMP degradation. Sildenafil and avanafil interact with PDE5, so their concentration-dependent PD relationship can determine how an emerging concentration trajectory is translated into downstream modeled response. Consequently, onset is not determined by absorption alone. It represents the intersection of an evolving PK concentration profile with a specified PD response function. This distinction is developed in no → cGMP cascade differences.
PK and PD variability can independently shift modeled onset. PK variability changes the concentration trajectory through differences in absorption rate, systemic input timing, distribution, metabolic turnover, or clearance. A steeper or earlier concentration rise can therefore cross a fixed PD response region at a different modeled time. PD variability produces a different mechanism: changes in potency can shift the concentration scale of response, changes in slope can alter the steepness of the transition, and changes in pathway sensitivity can modify how concentration-dependent PDE5 interaction propagates through the NO/cGMP signaling model. These PD changes can shift the modeled onset point without requiring a change in absorption or systemic exposure. Conversely, a change in PK exposure can shift onset while the concentration–effect relationship remains unchanged. Separating these mechanisms prevents an early timing difference from being attributed automatically to either absorption or intrinsic PD sensitivity. The distinction between exposure-driven and concentration–effect-driven variability is described through pk variability and pd variability.
| PD Domain | Onset Interaction Determinant | Link |
|---|---|---|
| Potency | Determines concentration scale for the modeled response. | pd variability |
| Slope | Determines rate of modeled effect change with concentration. | pd variability |
| Pathway Sensitivity | Determines modeled sensitivity of downstream NO/cGMP response to PDE5 interaction. | no → cGMP cascade differences |
| Maximal Modeled Effect | Defines the upper limit of the modeled response. | duration comparison |
Mechanistic onset differences arise from the interaction between early PK exposure geometry and the PD concentration–effect relationship. On the PK side, absorption rate, dissolution, gastric emptying, intestinal availability, and systemic input timing determine how rapidly concentration begins to rise. Distribution can simultaneously remove drug from the central compartment and alter the shape of the early concentration trajectory. Early metabolic turnover can also modify the emerging profile as absorption continues. On the PD side, potency determines the concentration scale of the modeled response, slope determines response steepness, and pathway sensitivity influences how concentration-dependent PDE5 interaction propagates through the downstream signaling system. Sildenafil and avanafil can therefore produce different modeled onset geometries through differences in either PK parameters, PD parameters, or their interaction. Onset is consequently a combined PK/PD timing construct rather than a single absorption parameter or isolated concentration measurement.
Absorption rate determines how quickly drug enters the systemic compartment, while systemic input timing describes when and over what interval that entry occurs. Dissolution affects availability for absorption, and gastric emptying can shift the timing of intestinal entry. Once absorption begins, the emerging concentration is simultaneously influenced by distribution into peripheral compartments and by elimination processes. A faster systemic input can produce a steeper ascending concentration profile, while a slower input can spread the rise over a longer interval. Differences in absorption extent alter the magnitude of systemic exposure but do not necessarily produce the same temporal change as differences in absorption rate. The resulting early concentration geometry is therefore shaped by both the rate and extent of input and by concurrent distribution and elimination. A modeled onset point occurs when this evolving concentration trajectory reaches a defined region of the PD concentration–effect relationship. Consequently, systemic input timing establishes the PK foundation for onset but does not by itself define the complete PK/PD onset construct.
PK and PD variability can independently modify modeled onset. PK variability changes the concentration-time trajectory through parameters such as absorption rate, systemic input timing, distribution, metabolic turnover, and clearance. These changes can move the concentration trajectory relative to a fixed concentration–effect curve. PD variability changes the concentration–effect relationship itself. Differences in potency can shift the concentration range associated with a defined modeled response, while slope changes the steepness of the response transition. Pathway sensitivity can further alter how changes in concentration-dependent PDE5 interaction propagate through the modeled NO/cGMP system. Therefore, a change in onset timing does not necessarily indicate altered absorption. It may instead reflect a change in PD coupling, or a combination of PK and PD changes. Conversely, a PK exposure difference can shift modeled onset even when intrinsic PD parameters remain constant. Separating these sources of variability allows early timing differences to be attributed to specific mechanistic determinants rather than treated as one undifferentiated onset parameter.
Onset, peak, and duration represent different temporal regions of a PK/PD trajectory. Onset concerns the early portion of the concentration-time profile and the point at which that trajectory enters a defined region of the concentration–effect relationship. Peak geometry concerns the later point at which the balance among systemic input, distribution, and elimination produces a maximum or near-maximum concentration or modeled response. Duration geometry concerns persistence and decline after the peak region and is strongly influenced by distribution, metabolic turnover, and clearance. These regions are connected but are not interchangeable. A parameter that accelerates early absorption can shift onset without producing the same proportional change in terminal decline. Likewise, a clearance difference can alter duration while leaving the initial absorption-driven rise relatively unchanged. PD potency and slope can also shift the modeled onset or peak response without changing the underlying PK concentration trajectory. Separating the three regions therefore preserves the distinction between early input, peak formation, and later exposure persistence within the combined PK/PD model.